Additional Relevant Details "Eli Lilly and Boehringer Ingelheim announced positive top-line results from EMPA-REG OUTCOME, a long-term study evaluating Jardiance in more than 7,000 adults with type 2 diabetes at high risk of CV events. The primary endpoint was met, as Jardiance demonstrated superiority to standard of care in reduction of CV risk. Jardiance is the only glucose-lowering agent to have demonstrated CV risk reduction in a long term outcome trial.